亞洲 腫瘤免疫雙特異性抗體
腫瘤免疫雙抗：一個抗體，同時打兩個免疫目標。
8追蹤資產
0已核准
這個賽道在做什麼
雙特異性抗體一次結合兩個標靶。在腫瘤免疫領域，目的是同時鬆開免疫系統的兩個煞車（例如 PD-1／PD-L1 加 CTLA-4），或加上 4-1BB 這類活化訊號，或阻斷腫瘤用來躲過巨噬細胞的「別吃我」訊號 CD47。一個分子兩種功能，比合併兩種藥簡單，但安全性的平衡更難拿捏。PD-1/VEGF 雙抗與 T 細胞銜接器另有專頁，不列在這裡。
階段分布
第三期1 1
第二期1 1
第一／二期4 4
第一期2 2
國家分布
中國7 7
韓國1 1
資產表
| 排名 | 資產 | 國際非專利名稱 | 原研公司 | 國家 | 標的 | 機轉 | 最高階段 | 適應症 | 試驗登錄號 | 海外權利人 | 交易日期 | 首付款 | 總額上限 | 最新事件 | 最新事件日期 | 來源 | 來源日期 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Amulirafusp alfa (IMM0306) | amulirafusp alfa | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | China | CD47; CD20 | Anti-CD20 antibody fused to a CD47-binding SIRPα domain (mAb-Trap) | Phase 3 — China (2026-03) | Relapsed/refractory follicular lymphoma (lenalidomide combination) | NCT07355283 | NCT05805943 | None reported | — | — | — | Company reports first patient dosed in the follicular lymphoma Phase 3 trial | 2026-03-30 | 1 2 3 4 5 | 2026-03-30 |
| 2 | QLF31907 | — | Qilu Pharmaceutical Co., Ltd. | China | PD-L1; 4-1BB (CD137) | PD-L1 blockade with conditional 4-1BB costimulation | Phase 2 — China (2023-04; registry status unknown) | Advanced melanoma; urothelial carcinoma | NCT05823246 | NCT05150405 | NCT06394713 | None reported | — | — | — | Phase 2 melanoma results published in an ASCO 2026 abstract | 2026-06-01 | 1 2 3 4 5 6 7 | 2026-06-01 |
| 3 | IMM2902 | — | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | China | HER2; CD47 | HER2 antibody fused to a CD47-binding SIRPα domain (mAb-Trap) | Phase 1/2 — China (2022-02; registry status unknown) | HER2-expressing advanced solid tumors | NCT05805956 | NCT05076591 | None reported | — | — | — | US Phase 1 registry updated with SUSPENDED status | 2024-10-30 | 1 2 3 4 | 2024-10-30 |
| 4 | HB0036 | — | Shanghai Huaota Biopharmaceutical Co., Ltd. (Huahai group) | China | PD-L1; TIGIT | Dual immune-checkpoint blockade by a PD-L1/TIGIT bispecific antibody | Phase 1/2 — China / US (2022-08) | Advanced solid tumors | NCT05417321 | None reported | — | — | — | Phase 1/2 registry updated; recruiting | 2025-01-03 | 1 2 3 | 2025-01-03 |
| 5 | Q-1802 | — | QureBio Ltd. | China | CLDN18.2; PD-L1 | CLDN18.2 tumor targeting with PD-L1 checkpoint blockade | Phase 1/2 — China (2023-06; registry status unknown) | Advanced gastrointestinal tumors; gastric/gastroesophageal junction cancer | NCT05964543 | NCT04856150 | None reported | — | — | — | Company reports Phase 1b/2 combination data submitted for ASCO 2026 | 2026-01-28 | 1 2 3 4 | 2026-01-28 |
| 6 | PM1009 | — | Biotheus Inc. (BioNTech subsidiary) | China | TIGIT; PVRIG | Dual immune-checkpoint blockade by a TIGIT/PVRIG bispecific antibody | Phase 1/2 — China (registered 2024-09; not yet recruiting) | First-line hepatocellular carcinoma (PM8002 combination); advanced solid tumors | NCT06584071 | NCT05607563 | None reported | — | — | — | BioNTech announces completion of Biotheus acquisition and rights to its pipeline | 2025-02-03 | 1 2 3 4 5 | 2025-02-03 |
| 7 | BAT7104 | — | Bio-Thera Solutions, Ltd. | China | PD-L1; CD47 | PD-L1 and CD47/SIRPα checkpoint blockade by a bispecific antibody | Phase 1 — China / Australia (2022-01; trials completed) | Advanced solid tumors; advanced malignant tumors | NCT05767060 | NCT05200013 | None reported | — | — | — | China Phase 1 registry updated; completed | 2025-12-02 | 1 2 3 4 | 2025-12-02 |
| 8 | BH3120 | — | Hanmi Pharmaceutical Co., Ltd. / Beijing Hanmi Pharmaceutical Co., Ltd. | South Korea | PD-L1; 4-1BB (CD137) | PD-L1 blockade with 4-1BB costimulation (Pentambody) | Phase 1 — South Korea / US (2023-12) | Advanced or metastatic solid tumors; monotherapy or pembrolizumab combination | NCT06234397 | None reported | — | — | — | Phase 1 registry updated; recruiting | 2026-09-25 | 1 2 3 4 | 2026-09-25 |